Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study

Clinical Infectious Diseases

Volumn 56, Issue 6, 2013, Pages 817-824

  Manuel, Oriol ^a   Husain, Shahid ^b   Kumar, Deepali ^c   Zayas, Carlos ^d   Mawhorter, Steve ^e   Levi, Marilyn E ^f   Kalpoe, Jayant ^g   Lisboa, Luiz ^c   Ely, Leticia ^c   Kaul, Daniel R ^h   Schwartz, Brian S ⁱ   Morris, Michele I ^j   Ison, Michael G ^k   Yen Lieberman, Belinda ^e   Sebastian, Anthony ^l   Assi, Maha ^m   Humar, Atul ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d PIEDMONT HOSPITAL   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

more..

Author keywords

antiviral prophylaxis; late onset CMV disease; protection; Quantiferon CMV

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; GAMMA INTERFERON; GANCICLOVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTERFERON GAMMA RELEASE ASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; TREATMENT RESPONSE; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; CHEMOPREVENTION; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA RELEASE TESTS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TRANSPLANTS;

EID: 84874774789     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis993     Document Type: Article

References (23)

1. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4):S78-86.
2. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779-95.
3. Manuel O, Perrottet N, Pascual M. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. Expert Rev Anti Infect Ther 2011; 9:955-65.
4. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228-37.
5. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
6. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007; 20:412-8.
7. Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 2011; 91:251-5.
8. Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 2011; 92:1063-8.
9. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R transplant recipients. Am J Transplant 2005; 5:1065-70.
10. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22:76-98, Table of Contents.
11. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6:29.
12. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8:990-9.
13. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 8:1486-97.
14. Giulieri S, Manuel O. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 2011; 11:17-25.
15. Walker S, Fazou C, Crough T, et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERONCMV. Transpl Infect Dis 2007; 9:165-70.
16. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9:1214-22.
17. Humar A, Michaels M, Monitoring AIWGoID. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6:262-74.
18. Weseslindtner L, Kerschner H, Steinacher D, et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant 2012; 12:2172-80.
19. Clari MA, Munoz-Cobo B, Solano C, et al. Performance of the QuantiFERON- cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon- producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol 2012; 19:791-6.
20. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012; 93:195-200.
21. Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirus- specific CD8(+) T-cell responses using the QuantiFERON- CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol 2010; 82:433-40.
22. Lochmanova A, Lochman I, Tomaskova H, et al. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc 2010; 42:3574-7.
23. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008; 8:1749-54.